196 related articles for article (PubMed ID: 35840635)
1. Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma.
Liu C; Liu H; Dasgupta M; Hellman LM; Zhang X; Qu K; Xue H; Wang Y; Fan F; Chang Q; Yu D; Ge L; Zhang Y; Cui Z; Zhang P; Heller B; Zhang H; Shi B; Baker BM; Liu C
Sci Rep; 2022 Jul; 12(1):12068. PubMed ID: 35840635
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Antibodies against Intracellular Tumor Antigens.
Trenevska I; Li D; Banham AH
Front Immunol; 2017; 8():1001. PubMed ID: 28868054
[TBL] [Abstract][Full Text] [Related]
3. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
Front Immunol; 2020; 11():623. PubMed ID: 32425926
[TBL] [Abstract][Full Text] [Related]
4. Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies.
Li D; Bentley C; Yates J; Salimi M; Greig J; Wiblin S; Hassanali T; Banham AH
PLoS One; 2017; 12(4):e0176642. PubMed ID: 28448627
[TBL] [Abstract][Full Text] [Related]
5. T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy.
Duan Z; Ho M
Mol Cancer Ther; 2021 Sep; 20(9):1533-1541. PubMed ID: 34172530
[TBL] [Abstract][Full Text] [Related]
6. Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy.
Li Z; Gong H; Liu Q; Wu W; Cheng J; Mei Y; Chen Y; Zheng H; Yu X; Zhong S; Li Y
Immunology; 2020 Apr; 159(4):384-392. PubMed ID: 31849039
[TBL] [Abstract][Full Text] [Related]
7. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.
Verma B; Neethling FA; Caseltine S; Fabrizio G; Largo S; Duty JA; Tabaczewski P; Weidanz JA
J Immunol; 2010 Feb; 184(4):2156-65. PubMed ID: 20065111
[TBL] [Abstract][Full Text] [Related]
8. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.
Sun L; Guo H; Jiang R; Lu L; Liu T; He X
Tumour Biol; 2016 Jan; 37(1):799-806. PubMed ID: 26250457
[TBL] [Abstract][Full Text] [Related]
9. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.
Zhu W; Peng Y; Wang L; Hong Y; Jiang X; Li Q; Liu H; Huang L; Wu J; Celis E; Merchen T; Kruse E; He Y
Hepatology; 2018 Aug; 68(2):574-589. PubMed ID: 29443377
[TBL] [Abstract][Full Text] [Related]
10. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.
Liu H; Xu Y; Xiang J; Long L; Green S; Yang Z; Zimdahl B; Lu J; Cheng N; Horan LH; Liu B; Yan S; Wang P; Diaz J; Jin L; Nakano Y; Morales JF; Zhang P; Liu LX; Staley BK; Priceman SJ; Brown CE; Forman SJ; Chan VW; Liu C
Clin Cancer Res; 2017 Jan; 23(2):478-488. PubMed ID: 27535982
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201.
Trenevska I; Anderson AP; Bentley C; Hassanali T; Wiblin S; Maguire S; Pezzella F; Banham AH; Li D
PLoS One; 2021; 16(4):e0249967. PubMed ID: 33836029
[TBL] [Abstract][Full Text] [Related]
12. Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma.
Nakagawa H; Mizukoshi E; Kobayashi E; Tamai T; Hamana H; Ozawa T; Kishi H; Kitahara M; Yamashita T; Arai K; Terashima T; Iida N; Fushimi K; Muraguchi A; Kaneko S
Gastroenterology; 2017 May; 152(6):1395-1406.e10. PubMed ID: 28188748
[TBL] [Abstract][Full Text] [Related]
13. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.
Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M
Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595
[TBL] [Abstract][Full Text] [Related]
14. Opportunities and challenges for TCR mimic antibodies in cancer therapy.
Chang AY; Gejman RS; Brea EJ; Oh CY; Mathias MD; Pankov D; Casey E; Dao T; Scheinberg DA
Expert Opin Biol Ther; 2016 Aug; 16(8):979-87. PubMed ID: 27094818
[TBL] [Abstract][Full Text] [Related]
15. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
16. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
Wittman VP; Woodburn D; Nguyen T; Neethling FA; Wright S; Weidanz JA
J Immunol; 2006 Sep; 177(6):4187-95. PubMed ID: 16951384
[TBL] [Abstract][Full Text] [Related]
17. TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma.
Hussein MS; Li Q; Mao R; Peng Y; He Y
Front Immunol; 2023; 14():1114770. PubMed ID: 37215108
[TBL] [Abstract][Full Text] [Related]
18. Assessing vaccine potency using TCRmimic antibodies.
Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
[TBL] [Abstract][Full Text] [Related]
19. Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
Docta RY; Ferronha T; Sanderson JP; Weissensteiner T; Pope GR; Bennett AD; Pumphrey NJ; Ferjentsik Z; Quinn LL; Wiedermann GE; Anderson VE; Saini M; Maroto M; Norry E; Gerry AB
Hepatology; 2019 May; 69(5):2061-2075. PubMed ID: 30561769
[TBL] [Abstract][Full Text] [Related]
20. The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein.
Shen Y; Li YM; Zhou JJ; Zhou Z; Xu YC; Zhao WB; Chen SQ
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31408937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
